Danaher delivered beats on the top and bottom lines for the third quarter on Thursday. But shares of the life sciences and medical diagnostics company remain under pressure after management was forced to lower expectations for one of its key businesses. Revenue for the period ended Sept. 30 declined 11.5% organically year over year to $6.87 billion, outpacing analyst estimates of $6.63 billion, according to Refinitiv. When excluding the 8.
Driving this forecast is an expectation for biotechnology sales to be down in the high-teens percentage range, life sciences sales to be about flat , and for diagnostics to be down in the mid-teens percentage point range. The adjusted operating profit margin is expected to be 29% — slightly better than the Street's 28%.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Sumber: MarketWatch - 🏆 3. / 97 Baca lebih lajut »
Sumber: MarketWatch - 🏆 3. / 97 Baca lebih lajut »
Sumber: MarketWatch - 🏆 3. / 97 Baca lebih lajut »
Stocks extend slide, Chevron mega-deal, Apple slumps, 2-year auction on deck, Roivant drug saleStocks slide, Chevron mega-deal, Apple, 2-year auction, Roivant drug sale
Sumber: startelegram - 🏆 248. / 63 Baca lebih lajut »
Sumber: Newsweek - 🏆 468. / 52 Baca lebih lajut »
Sumber: MarketWatch - 🏆 3. / 97 Baca lebih lajut »